vs
Side-by-side financial comparison of Cambium Networks Corp (CMBM) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.
Cambium Networks Corp is the larger business by last-quarter revenue ($40.3M vs $20.6M, roughly 2.0× Pulmonx Corp). Cambium Networks Corp runs the higher net margin — -17.9% vs -66.3%, a 48.4% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -23.2%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -27.2%).
Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
CMBM vs LUNG — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $40.3M | $20.6M |
| Net Profit | $-7.2M | $-13.7M |
| Gross Margin | 36.6% | 77.9% |
| Operating Margin | -28.4% | -40.9% |
| Net Margin | -17.9% | -66.3% |
| Revenue YoY | -23.2% | -8.7% |
| Net Profit YoY | 71.0% | 5.5% |
| EPS (diluted) | $-0.26 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $20.6M | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | — | $21.5M | ||
| Q2 25 | — | $23.9M | ||
| Q1 25 | — | $22.5M | ||
| Q4 24 | $40.3M | $23.8M | ||
| Q3 24 | $44.7M | $20.4M | ||
| Q2 24 | $45.2M | $20.8M |
| Q1 26 | — | $-13.7M | ||
| Q4 25 | — | $-10.4M | ||
| Q3 25 | — | $-14.0M | ||
| Q2 25 | — | $-15.2M | ||
| Q1 25 | — | $-14.4M | ||
| Q4 24 | $-7.2M | $-13.2M | ||
| Q3 24 | $-34.5M | $-14.1M | ||
| Q2 24 | $-14.2M | $-15.3M |
| Q1 26 | — | 77.9% | ||
| Q4 25 | — | 77.6% | ||
| Q3 25 | — | 74.7% | ||
| Q2 25 | — | 72.1% | ||
| Q1 25 | — | 72.5% | ||
| Q4 24 | 36.6% | 74.0% | ||
| Q3 24 | 43.6% | 73.7% | ||
| Q2 24 | 32.5% | 73.7% |
| Q1 26 | — | -40.9% | ||
| Q4 25 | — | -43.8% | ||
| Q3 25 | — | -66.9% | ||
| Q2 25 | — | -62.0% | ||
| Q1 25 | — | -64.6% | ||
| Q4 24 | -28.4% | -56.5% | ||
| Q3 24 | -69.6% | -69.3% | ||
| Q2 24 | -27.2% | -75.2% |
| Q1 26 | — | -66.3% | ||
| Q4 25 | — | -46.1% | ||
| Q3 25 | — | -64.9% | ||
| Q2 25 | — | -63.6% | ||
| Q1 25 | — | -64.1% | ||
| Q4 24 | -17.9% | -55.4% | ||
| Q3 24 | -77.3% | -69.4% | ||
| Q2 24 | -31.5% | -73.7% |
| Q1 26 | — | $-0.33 | ||
| Q4 25 | — | $-0.25 | ||
| Q3 25 | — | $-0.34 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | $-0.26 | $-0.33 | ||
| Q3 24 | $-1.22 | $-0.36 | ||
| Q2 24 | $-0.51 | $-0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $61.6M |
| Total DebtLower is stronger | $67.6M | $37.3M |
| Stockholders' EquityBook value | $-3.2M | $45.8M |
| Total Assets | $173.7M | $120.0M |
| Debt / EquityLower = less leverage | — | 0.82× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.6M | ||
| Q4 25 | — | $69.8M | ||
| Q3 25 | — | $76.5M | ||
| Q2 25 | — | $75.5M | ||
| Q1 25 | — | $74.6M | ||
| Q4 24 | — | $70.9M | ||
| Q3 24 | — | $63.3M | ||
| Q2 24 | — | $63.5M |
| Q1 26 | — | $37.3M | ||
| Q4 25 | — | $37.1M | ||
| Q3 25 | — | $37.1M | ||
| Q2 25 | — | $37.1M | ||
| Q1 25 | — | $37.2M | ||
| Q4 24 | $67.6M | $37.2M | ||
| Q3 24 | $67.6M | $37.2M | ||
| Q2 24 | $68.9M | $37.2M |
| Q1 26 | — | $45.8M | ||
| Q4 25 | — | $54.1M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $69.1M | ||
| Q1 25 | — | $77.7M | ||
| Q4 24 | $-3.2M | $85.8M | ||
| Q3 24 | $1.9M | $93.9M | ||
| Q2 24 | $34.1M | $101.2M |
| Q1 26 | — | $120.0M | ||
| Q4 25 | — | $129.3M | ||
| Q3 25 | — | $138.3M | ||
| Q2 25 | — | $147.2M | ||
| Q1 25 | — | $150.7M | ||
| Q4 24 | $173.7M | $162.8M | ||
| Q3 24 | $194.3M | $167.4M | ||
| Q2 24 | $221.1M | $172.6M |
| Q1 26 | — | 0.82× | ||
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | 36.12× | 0.40× | ||
| Q2 24 | 2.02× | 0.37× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.4M | — |
| Free Cash FlowOCF − Capex | $-10.8M | — |
| FCF MarginFCF / Revenue | -26.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-21.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-8.2M | ||
| Q2 25 | — | $-3.9M | ||
| Q1 25 | — | $-13.2M | ||
| Q4 24 | $-10.4M | $-6.7M | ||
| Q3 24 | $8.9M | $-7.2M | ||
| Q2 24 | $2.4M | $-5.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-8.3M | ||
| Q2 25 | — | $-4.0M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | $-10.8M | $-6.8M | ||
| Q3 24 | $6.8M | $-7.7M | ||
| Q2 24 | $87.0K | $-6.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | -31.4% | ||
| Q3 25 | — | -38.4% | ||
| Q2 25 | — | -16.6% | ||
| Q1 25 | — | -60.0% | ||
| Q4 24 | -26.8% | -28.8% | ||
| Q3 24 | 15.2% | -37.6% | ||
| Q2 24 | 0.2% | -30.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | 1.1% | 0.5% | ||
| Q3 24 | 4.8% | 2.0% | ||
| Q2 24 | 5.1% | 2.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBM
| Enterprise | $16.6M | 41% |
| Point To Multi Point | $16.4M | 41% |
| Other | $5.8M | 14% |
LUNG
Segment breakdown not available.
